Treatment News : Reformulated Vaginal Microbicide Gel Looks Promising for Rectal Use

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » April 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


April 9, 2013

Reformulated Vaginal Microbicide Gel Looks Promising for Rectal Use

A reformulated vaginal microbicide gel has proved safe and well tolerated in HIV-negative women and men using it rectally. Microbicide Trials Network–sponsored researchers at the National Institutes of Health (NIH) tested a reduced glycerin formulation of a tenofovir 1 percent gel and published their findings in the journal PLOS ONE. This study was the first to reformulate the gel by using less glycerin in hopes of creating a product more amenable to rectal use. Beginning in October 2010, the study included 65 men and women at three sites: the University of Pittsburgh, the University of Alabama at Birmingham and Fenway Health in Boston.

The participants were randomly divided into four groups. Three received one of three different products over the period of one week: the reduced glycerin formulation of tenofovir gel, a placebo gel without tenofovir, or a gel that contained the spermicide nonoxynol-9. The fourth group only received the study’s procedures and tests, which included physical and rectal exams, and no gel.

With no significant difference in side effects between groups, 80 percent of the participants reported minor side effects from the gels and 18 percent reported moderate side effects. Ninety-four percent of the participants used the gels daily as directed. Eighty-four percent of the reformulated gel group said they would likely use the gel again, compared with 93 percent of the placebo gel group and 63 percent of those in the nonoxynol-9 group.

The investigators are planning a Phase II trial of the reformulated gel in 186 men who have sex with men and transgender women.

To read the study, click here.

To read a release on the study, click here.

Search: microbicide, rectal, gel, Microbicide Trials Network, tenofovir, PLOS ONE, University of Pittsburgh, University of Alabama at Birmingham, Fenway Health, nonoxynol-9.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (4 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.